Thursday, March 08, 2018 10:06:36 AM
On March 5, 2018, we entered into private placement transaction and executed a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers identified therein (collectively, the “Purchasers”) providing for the issuance and sale to the Purchasers of an aggregate of 600 shares of our Series E Convertible Preferred Stock (the “Preferred Shares”) for gross proceeds to the Company of $600,000. Each Preferred Share is initially convertible into approximately 12,500 shares of our Common Stock for an aggregate total of 7,500,000 shares of our Common Stock (the “Conversion Shares”). The terms of the Preferred Shares include antidilution provisions. We closed this transaction on March 5, 2018.
The Preferred Shares do not have voting rights except as required by law and are not entitled to a dividend. When issued, the Conversion Shares will have the voting rights afforded to all shares of Common Stock. The Preferred Shares have a liquidation preference equal to the initial purchase price.
Pursuant to the Certificate of Designati on which authorized the Series E Convertible Preferred Stock, the Preferred Shares may be converted at any time at the option of the Purchasers into shares of our Common Stock at a conversion price of $0.08 per share (the “Conversion Price”). The Certificate of Designation contains price adjustment provisions, which may, under certain circumstances reduce the Conversion Price on several future dates according to a formula based on the then-current market price for our common stock
If the parties so agree, then the Company may sell up to an additional 600 shares of its Preferred Shares on the terms identical to those upon which the first 600 shares were sold. In that event, the Company will then also be obligated to issue the purchasers a warrant for up to 100% of the total shares of our Common Stock into which all of the Preferred Shares sold at either time could be converted. The warrant would have an exercise price equal to the then-current conversion price for the Preferred Shares, three-year term, and include a cashless-exercise feature.
Recent GOVX News
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:48 PM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 06:13:27 PM
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement • GlobeNewswire Inc. • 01/29/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:03:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2024 09:00:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM